About Prevail Therapeutics
At Prevail Therapeutics, we are developing novel gene therapies that target the root genetic causes of Parkinson’s disease and other neurodegenerative disorders. Our mission is to translate recent advances in human genetics and gene therapy technology into medicines that slow or stop the neurodegenerative process. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders.
Prevail was formed in 2017 and we are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City.
Prevail Therapeutics was acquired by Eli Lilly and Company in January of 2021, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the www.lilly.com website.
|
|
|
51-200 employees
View all Prevail Therapeutics employees
|
|
Biotechnology
|
|
430 E 29th St, New York, US
|
|
2017
|
|
Biotechnology, Gene Therapy, Cmc, Regulatory, Pharmaceuticals, Discovery, Clinical, Neurodegenerative Diseases, Drug Development, Parkinson's Disease
|
Prevail Therapeutics Alternatives
Prevail Therapeutics Staff Directory
Search Prevail Therapeutics Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
